Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the sponsor.

This medicine is now known as atinumab.

On 19 January 2009, orphan designation (EU/3/08/605) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/k class for the treatment of spinal cord injury.

The sponsorship was transferred to Novartis Europharm Limited, Ireland, in May 2018.

Key facts

Active substance
Recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/kappa class (atinumab)
Disease / condition
Treatment of spinal cord injury
Date of first decision
EU designation number

Sponsor's contact details

Novartis Europharm Limited
Vista Building
Elm Park
Merrion Road
Dublin 4
Tel. +41 61 324 11 11 (Switzerland)

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating